Category: St. Jude MedicalSyndicate content

Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup

September 17, 2014 by Arezu Sarvestani

Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.

TCT 2014 Roundup

Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.

Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.

Study: CardioMEMs implanted heart monitor safe for renal failure patients

September 16, 2014 by Arezu Sarvestani

New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.

Study: CardioMEMS' implanted sensor safe for renal failure patients

St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.

TCT 2014 Roundup

September 15, 2014 by Brad Perriello

A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.

TCT 2014 Roundup

Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:

TCT 2014: TAVI takes center stage

September 15, 2014 by Brad Perriello

Transcatheter aortic valve implants take center stage at the annual Transcatheter Cardiovascular Therapeutics conference with the latest data dumps from rivals Medtronic and Edwards Lifesciences.

TCT 2014: TAVI takes center stage

St. Jude Medical hits 'pause' on Portico TAVI device

September 15, 2014 by Brad Perriello

St. Jude Medical hits 'pause' on implantations of its Portico replacement heart valve after CT scans turned up a potential problem with the devices.

St. Jude Medical hits 'pause' on Portico TAVI trial

Failure of Medtronic's Symplicity-3 trial doesn't mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

September 4, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

St. Jude cries victory with its quadripolar leads

September 4, 2014 by Arezu Sarvestani

St. Jude Medical says that its Quartet quadripolar leads "performed better than bipolar leads of any kind" in a recent mega-study.

St. Jude cries victory with its quadripolar leads

Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp